Shares of French biotechnology firm Carbios surged following the release of detailed plans for its flagship industrial project in Longlaville. While the commencement of production has been pushed to the first half of 2028, investors responded positively to the outlined financial structure for the €230 million enzymatic recycling plant.
Market Response and Share Performance
The announcement triggered a significant rally in the company’s stock price. Carbios shares advanced by 11.59 percent to €8.09. This move further distances the equity from its 52-week low of €4.89, though it remains approximately 30 percent below its year-to-date level and well under the 52-week high of over €15.
A Partnership-Based Financial Model
The total cost for the facility, designed to scale enzymatic PET recycling to an industrial level, is now firmly established. Carbios has devised a funding strategy aimed at keeping the substantial project debt off its corporate balance sheet. The plan centers on the subsidiary Carbios 54.
This approach involves bringing in minority partners, alongside engagement with partner banks and French investors. The goal of this partnership structure is to deconsolidate the project’s liabilities. Public grant funding, already secured, will contribute €42.5 million to the total cost. The company’s existing pre-marketing agreements for the plant’s output provide evidence of future capacity utilization, strengthening the project’s commercial rationale.
Should investors sell immediately? Or is it worth buying Carbios?
Operational Readiness and Leadership
From an operational liquidity perspective, Carbios reports a solid position. The company expects to hold cash reserves of around €60 million by the end of 2025, which it deems sufficient for its ongoing business activities. The projected cash consumption for 2026 is estimated at approximately €20 million, providing a financial runway that extends beyond twelve months.
To bolster the execution of the industrial scale-up, Carbios has made a key appointment. Benoît Grenot, former head of a specialty chemicals group, has been named Deputy CEO with immediate effect. His mandate is to ensure operational excellence in delivering the Longlaville plant, underscoring management’s focus on adhering to the revised 2028 timeline without further delays.
Upcoming Financial Disclosure
The market will gain further insight into the company’s financial health on April 17, 2026, when Carbios publishes its full-year 2025 results. This report will reveal the effectiveness of cost-reduction measures implemented in the previous year and assess whether the company’s financial buffer is adequate for its ambitious objectives.
Ad
Carbios Stock: Buy or Sell?! New Carbios Analysis from March 31 delivers the answer:
The latest Carbios figures speak for themselves: Urgent action needed for Carbios investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 31.
Carbios: Buy or sell? Read more here...
